July 14, 2026 · Form 4 insider transaction
Jamil Khurram bought 16,250 shares of Galectin Therapeutics Inc. at $3.04 per share, a transaction worth $49.4K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026